GI 5182A

IN THE CALLERY TATES PATENT AND TRADEMARK OFFICE

APPLICANT : Hewick et al

GROUP ART UNIT: 1814

SERIAL NO.: 07/800,364

EXAMINER: K. Furman

FILED

: 26 November 1991

TITLE

: BONE AND CARTILAGE

INDUCTIVE PROTEINS

November 11, 1992

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

I hereby certify that this correspondence is beindeposited with the United States Postal Service a first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washing ton, D.C. 20231, on

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

Pursuant to the duty to submit DNA and amino acid sequence in computer readable form, this affirms that to the best of my knowledge and belief, the content of the SEQUENCE LISTING as provided after the specification and before the claims in the above-identified patent application and the computer readable copy of said SEQUENCE LISTING provided herewith are the same.

Respectfully submitted,

Date: MV. 12, 1992

Ellen J./Kapinos Reg. No. 32,245

Attorney for Applicant

87 CambridgePark Drive Cambridge, MA 02140 (617) 876-1170

GI 5182A
THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Hewick, et al

Application Serial No.

07/800,364

:

Filing Date

26 November 1991

For

Bone and Cartilage Inductive Proteins

November 11, 1992

Box Sequence Honorable Commissioner of Patents and Trademarks Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

Alla J. Kapino

STATEMENT PURSUANT TO 37 CFR 1.825 (a)

Sir:

Pursuant to the attached notice dated August 12, 1992 received from the Patent and Trademark Office that the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 because Sequence to human BMP-8 in Fig. 2 does not comply with the sequence rules, applicant herewith submits an amended Sequence Listing and Preliminary Amendment.

Please substitute this amended Sequence Listing for the originally-filed Sequence Listing. The Sequence Listing and enclosed diskette contain amendments to SEQ ID NOS 1-12 to correct defects and now contains SEQ ID NOS. 1-14.

In addition, the Application Serial Number and filing date are now available and have been provided in the appropriate location in the Sequence Listing.

These amendments present no substantive changes to the Sequences as originally filed. No new matter has been added.

Respectfully submitted,

Date: Nov. 12, 1997

Ellen J. Kapinos

Reg. No. 32,245

Attorney for Applicant

87 CambridgePark Drive Cambridge, MA 02140

NOTICE TO MIPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows: 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached. 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b). 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c). 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows: _ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823. c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: Ad. Other: Seguances to human BMPS 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d). 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e). 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f). 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c). 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _ APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 3/7 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.

> Examining Group <u>18</u>14 (703) 308- <u>4216</u>

For: Manager, Application Processing Division

(703) 308-1202 or 308-_